Idiopathic pulmonary fibrosis (IPF) is characterized by accumulation of alveolar macrophages spontaneously releasing exaggerated amounts of the potent mesenchymal cell growth factor platelet-derived growth factor (PDGF). To evaluate the relative contribution of the two PDGF genes to this process, PDGF-A and -B gene transcription rates and mRNA levels were examined in normal and IPF alveolar macrophages. While normal alveolar macrophages constitutively transcribe both PDGF-A and PDGF-B genes, LPS stimulation increases the transcription of both genes more than threefold. Importantly, IPF alveolar macrophages spontaneously transcribe both genes at a rate similar to that observed for normal macrophages after in vitro stimulation. Consistent with the transcription data, normal macrophages contain mRNA for both PDGF-A and -B, but PDGF-B mRNA is 10-fold more abundant. Strikingly, in IPF, both PDGF-A and -B mRNA levels were markedly increased, with persistence of the 10-fold dominance of PDGF-B mRNA. Thus, the exaggerated release of PDGF by IPF alveolar macrophages is likely modulated by upregulated PDGF gene transcription rates and concomitantly increased mRNA levels and the persistent 10-fold excess of B > A PDGF mRNA suggests that the PDGF released by alveolar macrophages is likely mostly of the potent B-chain homodimeric form. (J. Clin.
Introduction
Alveolar macrophages, pulmonary representatives of the mononuclear phagocyte system of bone marrow-derived cells, play a central role in normal wound healing and pathogenic fibrosis by virtue of their ability to release a variety of inflammatory mesenchymal cell chemoattractants and polypeptide growth factors (1) (2) (3) (4) . The most potent of these polypeptides is platelet-derived growth factor (PDGF),' a 30-kD dimer of two disulfide-linked polypeptides (5) (6) (7) . In addition to serving as a proceed through the early Gl phase ofthe growth cycle, PDGF can modulate cell motility, including chemotaxis (5) (6) (7) . Recent studies have demonstrated that human alveolar macrophages from the lungs of individuals with idiopathic pulmonary fibrosis (IPF), a chronic, fatal lung disorder characterized by diffuse fibrosis of the alveolar walls, spontaneously release exaggerated amounts of PDGF compared with macrophages from normal individuals. This suggests that PDGF released by alveolar macrophages in the lower respiratory tract is important in the pathogenesis of pulmonary fibrosis by modulating the accumulation of mesenchymal cells in the alveolar walls (8) .
There are two human PDGF genes, denoted A and B. PDGF-A is a seven exon gene spanning 24 kb on chromosome 7 at p2l-p22 (9, 10) . The A chain polypeptide occurs in two variants resulting from alternative splicing of exon VI; the resulting 23-kD precursor proteins differ in size by 15 amino acids (11, 12) . PDGF-B is also a seven exon gene of 24 kb, but is located on chromosome 22 at ql2.3-ql 3.1 and codes for a single 27-kD precursor protein (13) (14) (15) . The PDGF-B gene is also known as the c-sis protooncogene, a normal cellular gene with close homology to the v-sis transforming gene of the simian sarcoma virus that exerts its transforming properties by directing the target cells to produce a potent mitogen abundantly in an autocrine fashion, thus subverting the normal control of mesenchymal cell growth in which the growth stimuli are external to the cell and are rate limiting (16) (17) (18) (1, 20) . Seven were untreated, one was receiving prednisone (20 mg/d), and two were receiving cyclophosphamide (50 and 100 mg/d, respectively). Normals included eight nonsmoking individuals (5 males, 3 females; mean age, 38±4 yr) with no history of lung disease. All had normal physical examination, chest roentgenograms and lung physiology. All data are presented as mean±SEM; statistical comparisons were made using the two-tailed Student's t test.
Isolation ofalveolar macrophages. Alveolar macrophages were recovered by bronchoalveolar lavage as previously described (21) The PDGF-B gene probes were derived from pPB220, a 0.9 kb PDGF-B cDNA cloned after reverse transcription of RNA from LPSstimulated (5 h, 37°C) human blood monocytes followed by amplification of PDGF-B cDNA using the polymerase chain reaction and PDGF-B exon-specific oligonucleotide primers (23) . The cDNA probe pPB220 encompassed 66 bp from the 3' end ofexon I, all ofexons II-VI and 94 bp from the 5' end of exon VII.
As a control, a 2.3 kb y-actin cDNA pHF-yA-I was utilized (24) .
Quantification ofPDGF-A and -B gene transcription rates. PDGF-A and PDGF-B gene transcription rates were quantified by transcription "run off" (25, 26 pHFyA-l) in the presence of 50% formamide and I10% dextran sulfate.
Filters were then washed, subjected to autoradiography, and autoradiograms were scanned (2202 Ultrascan Laser Densitometer, Pharmacia-LKB, Piscataway, NJ). The relative transcription rates were expressed as arbitrary densitometric units.
Evaluation of PDGF-A and -B mRNA transcripts. Total cellular RNA was purified-from-macrophages by the acid guanidium-thiocyanate-phenol-chloroform extraction method (27). Northern analysis was carried out using total cellular RNA for PDGF-B and y-actin transcripts and (because preliminary studies showed it was in low abundance) poly A' RNA (obtained by oligo-dT cellulose chromatography) for PDGF-A transcripts. PDGF-B mRNA transcripts were evaluated with the PDGF-B cDNA probe pPB220, -y-actin transcripts were evaluated with the y-actin cDNA pHFyA-1, and PDGF-A transcripts with the PDGF-A cDNA, Dl. All probes were labeled to high specific activity with [32P~dCTP (3000 Ci/mmol, Amersham) by the random hexonucleotide primer method (28) .
PDGF-A, PDGF-B, and y-actin mRNA transcripts were all quantitated in total cellular RNA with PDGF-A, PDGF-B, and y-actin cRNA standard curves, respectively, to ensure comparability. Because oftheir low abundance PDGF-A mRNA transcripts were quantified in total cellular RNA using a solution hybridization/RNase protection assay (29) scripts were easily detectable in all three groups of macrophages, and appeared to be of similar intensity. These qualitative observations were confirmed by direct quantification of mRNA transcript levels (Fig. 3) . In this regard, IPF was associated with 4-fold increase in PDGF-A mRNA levels, as was LPS stimulation (P < 0.05, both compared to normal; A). The same was true for PDGF-B where there was a 4-fold increase in PDGF-B mRNA levels in IPF and LPS stimulated macrophages (P < 0.05, both comparisons to normal; B), whereas y-actin mRNA levels were similar in all three groups (P > 0.5, all comparisons; C). Interestingly, however, in all groups, PDGF-B transcript numbers dominated, with levels 10-fold greater than PDGF-A mRNA.
Discussion
Alveolar macrophages are believed to play a central role in the pathogenesis of pulmonary fibrosis by virtue of their ability, when activated, to release a variety of polypeptide mediators that act as chemoattractants and mitogens for fibroblasts (see Reference 1 for review). The most potent ofthese polypeptides is PDGF, a molecule capable of functioning in the picomolar range (5-7). Direct evidence for a role of PDGF in the pathogenesis of pulmonary fibrosis comes from the observation that alveolar macrophages recovered from the lungs of individuals with idiopathic pulmonary fibrosis are spontaneously releasing approximately 0.7 pmol PDGF/106 alveolar macrophages, a level fourfold above that of normal resting alveolar macrophages, and comparable to the amount of PDGF released by alveolar macrophages activated in vitro by inflammatory stimuli (8) . Furthermore, it is known that fibroblasts normally express PDGF receptors and respond to exogenous PDGF by proliferating (5, 7). A caveat is that there is no direct evidence that the proliferating fibroblasts observed in the lungs of indi- (5-7, 33, 34) . In contrast, the PDGF molecule composed of A-A homodimers does not serve as a chemoattractant and is only weakly mitogenic (7, 33, 34 The fact that both the IPF alveolar macrophages and the LPS stimulated normal alveolar macrophages have increased levels of A and B transcripts is consistent with the fact that the transcription of both genes is increased in these macrophages. However, the fact that both IPF and LPS stimulated macrophages have 10-fold more PDGF-B transcripts than PDGF-A transcripts is of interest in the context that in both circumstances there is approximately equal (albeit increased compared to normal resting macrophages) transcription rates for both the PDGF-B and PDGF-A genes. This observation is unexpected and suggests that PDGF-B and -A gene expression is differentially regulated at the level of mRNA accumulation. The actual mechanism(s) by which PDGF-A mRNA levels are selectively reduced compared to PDGF-B mRNA levels in alveolar macrophages is not known. Unfortunately, the limited number of alveolar macrophages available precludes further analysis of this dichotomy using presently available methods.
In the context of the central role of the alveolar macrophage in the pathogenesis of IPF (1), and the likelihood that B-B homodimers are the form of PDGF being released in this disease, the observation that the PDGF-B gene is upregulated in IPF macrophages similar to that ofactivated normal macrophages has therapeutic implications for this disorder. Although a causal relationship has not been definitively established, the increased alveolar macrophage PDGF gene expression seen at all levels and the increased alveolar fibroblast proliferation observed in IPF patients provide a specific target to evaluate the effect of various therapeutic modalities. In this regard, if a therapeutic regimen does not suppress the upregulated transcription of the PDGF-B gene, it likely will not suppress the exaggerated accumulation of fibroblasts within the alveolar walls in the disease. Also, the parallel increase in PDGF-B gene transcription and mRNA levels suggests that transcription is an important regulatory point in -PDGF gene expression in alveolar macrophages. This suggests that one therapeutic target for this disease might aim at downregulating alveolar macrophage PDGF-B gene transcription and mRNA accumulation. For example, this might be accomplished by transferring an artificial antisense (35) PDGF gene driven by the normal PDGF-B gene promoter into alveolar macrophages of these individuals, resulting in the suppression of the burden of this potent chemotactic and mitogenic signal in the lungs.
